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OBJECTIVES: Statins have potential protective effects against cancers but no stud-
ies have focused on patients with chronic hepatitis B virus (HBV) infection. The
purpose of this study was to investigate the association between the use of statins
in HBV-infected patients and the risk of hepatocellular carcinoma (HCC).
METHODS: We conducted a population-based cohort study from the Taiwan Na-
tional Health Insurance Research Database. A total of 33,413 HBV-infected patients
were included as the study cohort. Each subject was individually tracked from 1997
to 2008 to identify incident cases of HCC since 1999. Subsequent use of statin, other
lower-lipid agents, aspirin, and angiotensin-converting enzyme inhibitors were
identified. Cox proportional hazard regressions were employed to calculate the
hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between
the use of statins and the occurrence of HCC in the HBV-infected cohort. RESULTS:
There were 1,021 HCC cases from the HBV cohort during follow-up periods of
328,946 person-years; the overall incidence rates were 310.4 cases per 100,000 per-
son-years, respectively. There was a dose–response relationship between statin
use and the risk of HCC in the HBV cohort. The adjusted HRs were 0.66 (95% CI,
0.44–0.99), 0.41 (95% CI, 0.27–0.61), and 0.34 (95% CI, 0.18–0.67) for statin use 28-90,
91-365, and  365 cumulative defined daily doses (cDDD), respectively, relative to
no statin use ( 28 cDDD). CONCLUSIONS: Statin use may reduce the risk for HCC
in HBV-infected patients in a dose-dependent manner. Further mechanistic re-
search is needed.
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OBJECTIVES:Medical adherence to hormone therapy (HT: including tamoxifen and
aromatase inhibitors [AIs]) has been reported as an important prognosis factor for
breast cancer women. Since AIs is not the first-line treatment in postmenopausal
patients by the reimbursement policy in Taiwan, it is of interested to investigate
how the early-stage non-persistence and non-adherence to HT associated with
mortality of postmenopausal breast cancer patients. METHODS: The Taiwan
Health Insurance Research Database (NHIRD) was used to identify 17,101 newly
diagnosed (1999-2007) breast cancer women who were aged over 50 years olds and
received surgery (OP) and HT. The cancer treatments were further categorized into
adjuvant chemotherapy and radiation therapy (CT/RT), CT/nonRT, nonCT/RT and
nonCT/nonRT. The HT prescriptions were categorized into tamoxifen only and
tamoxifen/AIs. The prescription gap (PG) and medication possession ratio (MPR)
were calculated. Any PG180 days in the first treatment year and MPR80% were
defined as ‘early-stage non-persistence’ and ‘non-adherence’. Cox regressions
were used to estimate hazard ratios (HRs). RESULTS: There were 4.97% and 16.83%
identified as ‘early-stage non-persistence’ and ‘non-adherence’ toHT, respectively.
The MPRs of HT were similar across the four cancer treatment groups, but those
received CT/nonRT (5.69%) and CT/RT (6.92%) had a significant higher non-persis-
tence rate. Non-persistence in the first year (CT/RT: HR1.11, 95% CI0.86-1.45;
CT/nonRT: HR1.47, 95% CI1.17-1.85; nonCT/RT: HR2.34, 95% CI1.33-4.12;
nonCT/nonRT: HR2.19, 95% CI1.59-3.00) and non-adherence (CT/RT HR1.29,
95% CI1.09-1.53; CT/nonRT: HR1.40, 95% CI1.21-1.62; nonCT/RT: HR1.08, 95%
CI0.74-1.57; nonCT/nonRT: HR1.10, 95% CI0.92-1.31) were associated with in-
creased mortality. The non-persistence and non-adherence were significantly as-
sociated with increased risk of mortality in tamoxifen/AIs. CONCLUSIONS: Our
results support the association of early-stage non-persistence and non-adherence
toHTwith increasingmortality in postmenopausal breast cancer patients. It is vital
to improve prescribing persistence and adherence for enhancing clinical outcomes
and maximizing the efficiency of medical utilizations.
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OBJECTIVES: The general febrile neutropenia (FN) treatment in cancer patients in
Thailand is hospitalized intravenous antibiotics. Clinical evidence indicated the
efficacy of oral antibiotic treatment and early hospital discharge in the treatment of
FN patients. This study aimed to assess the cost effective treatment strategy for
adult cancer patients with low risk FN in Thailand. METHODS: A decision tree
model was constructed to compare 3 strategies: 1) treatment with ceftazidime in
hospital (HosIV); 2) treatment with oral amoxicillin-clavulanate plus ciprofloxacin
in hospital (HosPO); and 3) treatment with oral amoxicillin-clavulanate plus cipro-
floxacin and then early discharge in 24-48 hr after observing in hospital (Early D/C).
Health care perspective was used; hence, only direct medical costs (drug, hospital-
ization, out patient visit, and laboratory costs) were included. Cost data were ob-
tained fromLopburi Cancer Center. Outcomewasmeasured as quality-adjusted FN
episodes (QAFNE)which considered only 1 FN episode. Effective datawere based on
literature review. Incremental cost-effectiveness ratio (ICER)was analyzed. A series
of one-way sensitivity analyses were performed. RESULTS: In the base casemodel,
HosPO and Early D/Cwere cost saving when compared with HosIV. The cost saving
was equal to 64,028 and 65,801 THB respectively. Early D/C was themost dominant
strategy with lowest cost and highest QAFNE (5,686 THB and 0.63 QAFNE). The
result of one-way sensitivity analysis indicated that drug costs, utility for inpatient
IV, utility for inpatient oral and utility for early discharge showed the impact on
ICER.CONCLUSIONS: BothHosPO and Early D/C strategiesweremore cost effective
than HosIV in adult cancer patient with low risk FN in Thailand.
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OBJECTIVES: To summarize current hepatocellular carcinoma (HCC) treatment
patterns andhealth care expenditures during hospitalization amongChina’s urban
basic health insurance (BHI) beneficiaries and to identify trend in HCC treatment
expenditures from 2008 to 2010. METHODS: This was an encounter-based retro-
spective study using hospitalization claims database of the urban BHI enrollees.
Study subjects were patients aged 18 years or older, with the China urban citizens’
or employees’ BHI plan, and had at least one hospital admission with a discharge
diagnosis code of HCC (ICD-10 codes: C22.0 and C22.9) between 2008 and 2010.
Descriptive statistical analyses of treatment patterns and expenditures were
conducted. RESULTS: Totally, 2,765 hospitalization claims met inclusion criteria
and were extracted from the database. Systemic therapy (predominantly tradi-
tional Chinese medicine) was involved in 72% of hospitalizations and transarterial
chemoembolizationwas involved in 27%, followed by palliative therapy only (21%),
local ablation (5%), liver resection (4%), and radiation (3%). Thirty-five percent of
hospitalizations involved combined treatments. On average, HCC treatment ex-
penditure was CNY11,243 per hospitalization in 2008–2010, with annualized in-
crease of 21% from 2008 to 2010. The BHI plan covered a three-year average of 68%
(CNY7,613) of total expenses, while copayment accounted for 20% (CNY2,234).
Other self-paid expenses stabilized at CNY1,400 in 2008–2010. Length of stay
dropped from 21.0 days in 2008 to 17.2 days in 2010, yet the daily expense rose from
CNY460 to CNY848. CONCLUSIONS: Various treatments were used by hospitalized
HCC patients with urban BHI coverage. The most often used treatment was sys-
temic therapy. Health care expenditures per hospitalization increased tremen-
dously from 2008 to 2010. However, the drugs patients purchased outside hospitals
could not be captured in this database, which might underestimate the expendi-
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OBJECTIVES: To summarize the progress of epidemiology, treatment, and eco-
nomic burdens of type 2 diabetesmellitus (T2DM)with nephropathy complications
in China. METHODS: A systematic review method was performed to search and
refine the evidence of existing English and Chinese researches on T2DM and dia-
betic nephropathy. Literatures were searched from various databases including
Pubmed, Web of science, CNKI, etc. Five inclusion criteria include disease (T2DM
and nephropathy), population (Chinese patients), prevalence, treatment proce-
dure, and disease burden. Quality assessment and data extraction were imple-
mented by two reviewers independently and the differences between them were
resolved by consensus. RESULTS: Fifty-one articles were included in the review.
The results showed that the rising prevalence rate of diabetes in China has reached
a high level. The mortality of diabetic nephropathy (DN) has higher proportion of
34% in totalmortality of T2DMpatients than other DM complications, although the
researches related to DN are not yet enough. The western medicine treatment
strategies of T2DMwith chronic kidney diseasesweremore instructional, while the
treatment with Chinese herbal medicine was based on the principle of ‘syndrome
differentiation’, resulting in the difficulty to carry out multicenter clinical re-
searches to evaluate the treatment effect. Diabetes and its complications have
brought a heavy burden in China. The total economic burden of DM and its com-
plications reached 247.8 billion RMB in 2007 and varied among different cities and
between urban and rural areas. CONCLUSIONS: Evidence of prevalence and disease
burden of diabeteswasnot comprehensive in current researches onChinese patients,
especially for diabetic nephropathy. Information of diabetic complications should be
included in the content of cross-sectional diabetes surveys to provide more informa-
tion of the incidence and prevalence of DN. More intervention researches should be
conducted to actively prevent DM and chronic complications such as DN.
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OBJECTIVES:With an estimated 62.22million people suffering fromdiabetes, India
is fast becoming the “Diabetes Capital of theWorld”. VitaminD deficiency has been
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identified as a risk factor and also a prevalent condition for diabetic patients. Vita-
min D supplementation has been found to achieve appropriate glycemic control in
South Asian diabetic population. Due to mixed scientific evidence and lack of
guidelines, however, the extent of use of vitamin D in diabetic patients is under
studied. The objective of this studywas to understand the perceptions of vitaminD
supplements amongst adults with type 2 diabetes. METHODS: A literature review
was conducted to facilitate questionnaire designing. A separate version was cre-
ated for both the pharmacists and the physicians. These versions were differed to
reflect the scope of current Pharmacy and Medical practices in India. Being a pilot
study, a convenience sample of 10 physicians and 20 pharmacists was interviewed
from the suburban areas ofMumbai, India. Descriptive analyseswere performed to
compare the questionnaire responses. RESULTS: The relationship between vita-
min D deficiency and diabeteswas perceived to be positive in 70% of the physicians
and 75% of the pharmacists. The physicians perceived a pandemic of vitamin D
deficiency. Vitamin D supplements, however, were not commonly seen to be used
by diabetic patients. Amongst the users, the most common form of vitamin D
supplementwas in combinationwith calciumcarbonate. Use of fortified food items
with vitamin D and laboratory testing of serum D3 levels was also not popularly
done. CONCLUSIONS: In absence of pharmacy claims and utilization records, this
pilot study improves our understanding about the variability in the administration
of standard of care. Enhanced understanding of the perceptions and usage of nu-
tritional supplements like Vitamin D amongst many others can significantly im-
prove health outcomes in patients with Diabetes.
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OBJECTIVES: It is often unclear what the relative efficacies of available treatments
are due to lack of head-to-head clinical trial evidence. Indirect treatment compar-
ison (ITC) constitutes the standard method for comparing the relative efficacies of
treatments in the absence of head-to-head trial evidence. This study sought to
examine the difference in cost-effectiveness results between a series of decision
analyses compared to synthesising the clinical evidence with adjusted indirect
comparisons.METHODS: Cost-effectiveness analyses (CEA) of hypothetical Drug A
versus Drug B for three different scenarios were performed using a Markov model.
Three assumptions were made regarding the relative efficacies of these drugs: 1)
Drug A  Drug B; 2) Drug B 10% worse than Drug A and; 3) Drug B 20% worse than
Drug A. ITCs were undertaken for each scenario and the results were compared to
the results from the cost-effectiveness analysis. RESULTS: For Assumption 1, the
ITC showed a difference of up to 12%, whereas the CEA showed an almost perfect
overlay of the two scatterplots and the acceptability curves. In Assumption 2, the
ITC difference was up to 13%, while the scatterplots for the CEA were overlapping
and the acceptability curves clearly represented two different treatmentswith only
a small overlap at the upper range of the threshold. In Assumption 3, statistical
superiority of Drug A was demonstrated through the ITC, and the acceptability
curves of the CEA did not overlap. CONCLUSIONS: Themethodology introduced in
this paper is an alternative for decision makers to further examine the relative
effectiveness of two treatments when no head-to-head clinical trial data are avail-
able. A major limitation of this method is that detailed inputs (such as cost and
quality of life data) need to be readily available for the various treatments being
compared.
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OBJECTIVES: The Inverse Care Law, whereby health care services are less accessi-
ble to those in greater need, has been found to operate in a variety of health
systems. Tudor Hart asserted that market forces would exaggerate the maldistri-
bution of resources. The objective of this study is to examine whether the inverse
care law operates in a screening program for diabetic retinopathy (DR) in Hong
Kong (HK) with amixedmedical economy like other Asian countries.METHODS: A
randomized controlled trial has been conducted. All those with Type 1 or Type 2
diabetes from two public primary care clinics in Hong Kong were recruited and
then were randomly allocated into one group paying a fee of HK$60 (US$8) for
screening and the other group with free access. The outcomemeasures are uptake
of screening and extent of DR detected. RESULTS:After randomization, 1387 in free
and 1379 in pay groups were eligible for screening. 94.9%(1316/1387) and
92.6%(1277/1379)respectively agreed to participate in the study. The final screening
uptake rate were 88.5% (1165/1316)and 82.4% (1052/1277)respectively (P0.001).
Being in the pay group was associated with lower uptake of screening than in the
free group (OR0.59, 0.47-0.74) and lower prevalence of DR detected (20.3% VS
25.9%, P0.004). Subjects with higher socioeconomic status were more likely to
take up screening but with less DR detected. CONCLUSIONS: The inverse care law
appears to operate in a preventive intervention even with a relatively small co-
payment. There is a strong case for making effective preventive services free of
charge.
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OBJECTIVES: Evaluation and pricing mechanisms vary across countries for new
therapies. In Asia, South Korea has established a system based on cost-utility anal-
yses for pricing recommendations and subsequent negotiations. Japan, however,
uses a different pricing mechanism for new drugs that lack a comparator where a
premium could be applied to a breakeven price determined by a cost calculation
method. This study aims to compare the launch prices of drugs determined
through different pricing mechanisms. METHODS: Drugs listed and priced using
the cost calculation method in Japan from 2008 to 2011 were identified from the
MHLWwebsite. The same drugs and their published launch prices were identified
for South Korea. Using average annual exchange rates, South Korean prices were
converted to Japanese yen for comparison. Sensitivity analyses were conducted
using purchasing power parities for GDP. RESULTS: There were 54 new drugs
launched and priced using the cost calculation method in Japan. Among those, 24
(44%) were rewarded a premium from 10% to 40% with an average of 17.9%. Five
products were subject to a 5% price cut and the rest were priced at a breakeven
price. Only 16 (30%) of the 54 were identified for South Korea. In addition, for
products with several different dosage strengths available in Japan, only 1-2
strengths were reimbursed in South Korea. Each product listed in South Korea was
priced lower compared to its equivalent in Japan by 9% to 88% - or by 60% on
average. Results of a sensitivity analysis showed a wider variation in price differ-
ence with an average of 14% lower in South Korea. CONCLUSIONS: For products
priced using a cost calculation method in Japan, a more limited coverage with
lower listing prices was observed in South Korea. Further research is required to
study the impact of cost-utility analyses and pricing dynamics in the region.
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OBJECTIVES: To confirmwhether price premiums rewarded for new drugs in Japan
were justified by pharmacoecomic analysis. METHODS: We systematically re-
viewed the economic evaluation studies of new drugs launched in Japan between
April 2000 and March 2010 that were priced by the similar drug comparison
method, in which prices are set by comparison with prices of similar drugs. The
“Ichushi” and PubMed databases were used to search the published articles.
RESULTS: 220 drugs were priced by the similar drug comparison methods during
the 10-year period. In total, 22 published articles (16 drugs) were identified: 3 CUAs,
18 CEAs, and 1 CMA. In 10 out of 22 articles, only drug costs were included in the
cost estimation. There was a wide range of variation in outcomemeasures utilized
and life-years were only applied in 2 of 18 CEAs. The most common outcome used
was the proportion of patients who achieved target clinical results. Incremental
analysis was performed in 11 articles; however, the threshold for decision making
was mentioned in only 3 of these articles, even though 3 other studies did not take
into account because the results were dominant. While price premiums were re-
warded to all new drugs reviewed, only 8 of 16 drugs were cost-effective, 5 drugs
were not cost-effective, and the cost-effectiveness of 3 drugs was uncertain or
inconsistent between articles. CONCLUSIONS:Our literature review indicated only
halves of the drugs with premiums were reported to be cost-effective. However,
cost-effectiveness of the drugs could not be determined objectively because of a
wide range of variation in methods such as outcome measures and cost calcula-
tion. To utilize economic evaluations in policy making and clinical practice in
Japan, formulation ofmethodological standards is necessary to ensure consistency
among studies.
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OBJECTIVES: With the increasing demands for health care from rapid medical
technological advancement, the Taiwan National Health Insurance (TNHI) de-
mands for the development of systematic, transparent, and participatory pro-
cesses for selection of newhealth interventions to be included into theNHI Benefits
Schedule (NHIBS). Though evaluation of applications from the medical profession
for the listing of new health intervention on the NHIBS is recognized as a demo-
cratic decision making, its fairness and legitimacy have not been assessed. This
study aimed to assess the fairness and legitimacy of decisions in the priority setting
process for new health interventions into the NHIBS. METHODS: Both the four
conditions of accountability for reasonableness (Daniels and Sabin,2002):rele-
vance, publicity, appeals, and enforcement and the four steps of the trans-disci-
plinary model operational goals for priority setting in health care(Gibson et al,
2002):reasonableness, transparency, responsiveness, and accountability are used
to assess the fairness and legitimacy of the priority setting decisions. The data for
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